Accelerating drug discovery with a rapid, cost-efficient DNA assembly workflow

It typically takes around 10 years and millions to sometimes billions of dollars for most new drugs to make it to market. That’s why AstraZeneca is taking innovative new approaches to jump-start the early drug discovery process. Associate Principal Scientist, David Öling, and his team set out to optimize DNA construct development, knowing if they cracked the code on accelerating this step, it would affect all downstream processes and speed up early drug discovery.

Watch this webinar to learn how AstraZeneca:
  • Created FRAGment recycLER (FRAGLER), an algorithm to perform alignment, codon optimization and fragmentation of amino acid sequences that dramatically improves DNA assembly and plasmid generation

  • Reduced costs by 50%-90% to complete new synthetic DNA constructs by integrating FRAGLER with an algorithmic search functionality in Benchling

  • Achieved sequence search at scale, eliminating the need for new synthesis and lowering cost per iterative cycle

Watch now

Hosted by

David Öling, PhD
Associate Principal Scientist at AstraZeneca
Peter Fung, PhD
Product Marketing Manager, Audiences at Benchling

See Benchling in action

Helix Image